Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

World Health Organization Director-General Tedros Adhanom Ghebreyesus. Photo: Fabrice Coffrini/AFP via Getty Images

The World Health Organization has announced that it has stopped trials examining the potential of hydroxychloroquine as a treatment for the novel coronavirus after its multi-country trials showed "no benefit."

The big picture: The WHO paused last month tests of the anti-malarial drug after a review published in The Lancet stated potentially fatal health problems. It restarted trials after this paper was retracted, the BBC notes. The WHO said Wednesday its data "showed that hydroxychloroquine does not result in the reduction of mortality of hospitalized COVID-19 patients." The FDA ended on Monday its emergency use authorization of the drug that President Trump said previously he supported and used.

Go deeper

Sep 23, 2020 - Health

Johnson & Johnson begins large phase 3 trial of a coronavirus vaccine

Photo: Rafael Henrique/SOPA Images/LightRocket via Getty Images

Johnson & Johnson has begun phase 3 trials in the U.S. for its one-shot coronavirus vaccine, with plans to enroll the most participants of any trial yet.

The big picture: Johnson & Johnson's vaccine has several advantages over its competitors that make it a promising option for mass distribution: The company is initially testing it as one dose and it does not have to be frozen for storage.

The rebellion against Silicon Valley (the place)

Photo illustration: Sarah Grillo/Axios. Smith Collection/Gado via Getty Images

Silicon Valley may be a "state of mind," but it's also very much a real enclave in Northern California. Now, a growing faction of the tech industry is boycotting it.

Why it matters: The Bay Area is facing for the first time the prospect of losing its crown as the top destination for tech workers and startups — which could have an economic impact on the region and force it to reckon with its local issues.

Erica Pandey, author of @Work
1 hour ago - Economy & Business

Telework's tax mess

Illustration: Annelise Capossela/Axios

As teleworkers flit from city to city, they're creating a huge tax mess.

Why it matters: Our tax laws aren't built for telecommuting, and this new way of working could have dire implications for city and state budgets.